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Abstract
Background: Mortality for children with congenital heart disease (CHD) has declined with improved surgical
techniques and neonatal screening; however, as these patients live longer, accurate estimates of the prevalence
of adults with CHD are lacking.
Methods: To determine the prevalence and mortality trends of adults with CHD, we combined National Vital
Statistics System data and National Health Interview Survey data using an integrative systems model to determine
the prevalence of recalled CHD as a function of age, sex, and year (by recalled CHD, we mean positive response
to the question “has a doctor told you that (name) has congenital heart disease?”, which is a conservative lower-
bound estimate of CHD prevalence). We used Human Mortality Database estimates and US Census Department
projections of the US population to calculate the CHD-prevalent population by age, sex, and year. The primary
outcome was prevalence of recalled CHD in adults from 1970 to 2050; the secondary outcomes were birth
prevalence and mortality rates by sex and women of childbearing age (15–49 years).
Results: The birth prevalence of recalled CHD in 2010 for males was 3.29 per 1,000 (95 % uncertainty interval (UI)
2.8–3.6), and for females was 3.23 per 1,000 (95 % UI 2.3–3.6). From 1968 to 2010, mortality among zero to
51-week-olds declined from 170 to 53 per 100,000 person years. The estimated number of adults (age 20–64
years) with recalled CHD in 1968 was 118,000 (95 % UI 72,000–150,000). By 2010, there was an increase by
a factor of 2.3 (95 % UI 2.2–2.6), to 273,000 (95 % UI 190,000–330,000). There will be an estimated 510,000
(95 % UI: 400,000–580,000) in 2050. The prevalence of adults with recalled CHD will begin to plateau around
the year 2050. In 2010, there were 134,000 (95 % UI 69,000–160,000) reproductive-age females (age 15–49
years) with recalled CHD in the United States.
Conclusion: Mortality rates have decreased in infants and the prevalence of adults with CHD has increased
but will slow down around 2050. This population requires adult medical systems with providers experienced
in the care of adult CHD patients, including those familiar with reproduction in women with CHD.
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Background
Congenital heart disease (CHD) is one of the most com-
mon types of congenital malformations in the United
States (US), estimated to be between four and nine per
1,000 births, and without surgery it is are often incom-
patible with long-term survival [1–6]. Patients with
CHD can have mild disease with relatively little need for
medical care; however, others have complicated physi-
ology and require specialized care. One study found the
birth prevalence of moderate and severe CHD to be
about six per 1,000 births (and increases to 19 per 1,000
if serious bicuspid aortic valves are included) [4]. With
improved surgical techniques and increased neonatal
screening, the mortality in CHD has shifted from the
neonatal period into adulthood with a growing popula-
tion of adults with CHD [7–12]. However, the mortality
in CHD is still premature compared to the general
population and varies by socioeconomic status and race
[9, 11]. A recent systematic review estimated adults with
CHD to be around 3,000 per million [13] but this esti-
mate is not specific to the US. In addition, predictions
about the growth of this population over time are lack-
ing. This is important information for the healthcare
system because these patients are not cured and they
will continue to have excess mortality and suffer compli-
cations related to their CHD and surgical procedures
during their adult life [14, 15].
Because adults with CHD are a new patient population,
medical providers and care systems have relatively little
expertise with the unique issues of adult CHD patients.
These patients are complex not only because of their
CHD, but unique to this population is the interaction
between CHD and issues of young adulthood, including
reproduction, neurodevelopmental abnormalities, and gen-
etic syndromes for which CHD is only one part of the
phenotypic expression [16]. Thus, the expertise found in
pediatric medicine that has successfully treated these
patients for decades now must be developed in adult medi-
cine. Guidelines recommend that all adults with moderate
to severely complex CHD be evaluated by adult CHD
experts [17], which are currently few in number and insuf-
ficient for the growing adult CHD population [18]. How-
ever, many adult CHD patients, families, and medical
providers are unaware of the need for continued lifelong
subspecialty follow-up, especially in those with moderate
to severe disease [19–21].
Thus, to ensure the highest quality care for these com-
plex and unique patients, more accurate estimates of the
adult population with moderate to severe CHD are
needed, as well as future projections to help inform the
health care system [22].
We used integrative systems modeling [23],which com-
bines a mechanistic model of disease progression with a
statistical model of data likelihood, to simultaneously
estimate the prevalence and mortality of CHD in the US
from multiple data sources. From this model, we made
age-/sex-specific estimates of CHD population size from




The National Health Interview Survey (NHIS) has annu-
ally asked about CHD status in a large sample of the US
population [24]. Starting in 1997, it has included the fol-
lowing question for a random sample of individuals
younger than 18: “Looking at this list, has a doctor or
health professional ever told you that (selected child
name) had any of these conditions? … (9) congenital
heart disease?” We used positive response to this ques-
tion for years 1997 to 2011 to calculate the sex-/year-
specific measurements of prevalence for single-year age
groups, which we referred to as “recalled CHD” and
interpreted as a surrogate for the prevalence of moderate
to severe CHD. Recalled CHD is a vast underestimate of
the overall CHD prevalence but reflects the public
knowledge of CHD and potential cases that will encoun-
ter the health care system. In order to answer yes to the
question, the participant had to be familiar with the
term “CHD” and remember that their child had a heart
condition that is classified as a CHD. Recalled CHD is
likely biased to those with more moderate and severe
disease since these require multiple follow-up appoint-
ments or surgery. However, it is also possible that cases
of simple CHD were captured by this question. To avoid
age-differential nonresponse bias, we excluded age group
zero from the primary analysis.
CHD mortality
The National Center for Health Statistics in the US has
annually compiled data from all filed death certificates
and has made these data available on its Multiple-Cause
Mortality Files [25]. These files include demographic and
geographic information on the decedent and International
Classification of Disease (ICD) codes for the underlying
cause of death and contributing factors on the death cer-
tificate. Three versions of the ICD were used to code
causes of death in the mortality files (Additional file 1:
Table S1). The selected range of codes includes congenital
anomalies of the heart and great vessels and excludes
anomalies of the peripheral circulatory system. We de-
fined deaths associated with CHD if the records had any
mention of such codes as a cause of death or if the code
was listed in as an underlying cause of death. From this
we tabulated sex-/year-specific counts of CHD deaths for
single-year age groups for years 1968 to 2010.
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Population size
We used the Human Mortality Database (http://www.mor
tality.org/) and US Census Department 2012 Middle Series
projections to determine age-/sex-/year-specific US popula-
tion. We obtained CHD mortality rate data for each age/
sex/year group by dividing the CHD mortality counts by the
midyear population for each group.
The age-/sex-/year-specific data on CHD mortality rate
and CHD prevalence were used as inputs into our statistical
model of disease rates as function of age and time [26]. We
used parametric bootstrap resampling of the input data to
generate 95 % uncertainty intervals (UI). We multiplied the
appropriate population estimates by the estimated preva-
lence to produce estimates of the size of the CHD-
prevalent population by age, sex, and year.
Age- and sex-specific prevalence and with-condition
mortality rates for each year were calculated simultaneously
for all time periods (separately for males and females). We
examined trends in age-specific with-condition mortality
rates between 1968 and 2010 by year of death, pooled
across sexes. We present the data using the following age
groups: 0–51 weeks, 1–4 years, 5–9 years, 10–14 years,
15–19 years, and 20–65 years.
Modeling
We used the integrative systems model DisMod-PDE to
combine the prevalence and mortality data using a compart-
mental model of process and an offset log-normal model of
data [26]. DisMod-PDE is a nonlinear regression model that
uses a system of differential equations to relate age- and
time-specific progression of disease through a two-
compartment model. When modeling a congenital condition
such as CHD, the model simplifies to include only the age-/
time-specific excess-mortality hazard (χ) quantifying the flow
out of the with-condition compartment (C) and the time-
specific birth prevalence of the condition (C(0,t)). For more
detail, see Additional file 2. DisMod-PDE is a Bayesian
model, and we used weakly informative priors to allow the
data to inform the estimates as much as possible (Fig. 1).
Stock in compartment C was assumed to vary over age and
time and was smoothed across cohorts with second-order
smoothing of σ= 1. Hazard χ was assumed to also vary over
age and time and to have second-order smoothing across
ages, cohorts, and cross-smoothing with σ= 1. We used a
deterministic differential equation restricted to only com-
partment C and hazard χ of DisMod-PDE. Additional as-
sumptions of the model are the following: 1. there was no
incidence besides at birth; 2. there was no remission (no one
was cured from the condition); and 3. there was no protect-
ive effect associated with the condition. We also assumed
that the birth prevalence rate was constant over time, and
that the prevalence rate and excess mortality rate were con-
stant across cohorts before 1968. We conducted a sensitivity
analysis to quantify the influence of our assumptions; see
Additional file 3. When making projections, we conserva-
tively assumed that the birth prevalence and excess mortality
rate were constant across cohorts after 2010, as well. We
were unable to distinguish between disease severity based on
the NHIS data and therefore we estimate a single (age- and
time-specific) prevalence rate and excess mortality rate for
all recalled CHD. Analysis was undertaken using
DisMod-PDE software, with additional processing done with





The multiple-cause mortality files for all ages for 1968 to
2010 contain records for 92.4 million deaths by any
cause. We identified 288,813 deaths (0.31 %) associated
with a CHD. In 73.4 % of these deaths (212,116, or
Fig. 1 Integrative systems model combines mortality and prevalence data in a non-linear regression framework, based on an age- and time-specific
compartmental model of disease progression
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0.23 % of all), the CHD was the underlying cause, i.e.,
the death was coded as due to a CHD. Between 1968
and 2010, the cause-specific mortality rate for all ages
declined 71 %, from 4.9 to 1.4 per 100,000 person-years
(PY) (Fig. 2). The mortality was higher among males (1.5
per 100,000) than among females (1.3 per 100,000).
Among zero to 51-week-olds, it declined 69 % whereas
among adults aged 20–64 years, the mortality declined
55 %. The percentage of CHD deaths that occur during
the first year of life has declined from 61 % in 1968 to
46 % in 2010.
CHD prevalence
The NHIS data from 1997 to 2011 contains recalled
CHD status for 180,766 individuals, from which our
model estimates that the birth prevalence of recalled
CHD in 2010 for males was 3.29 per 1,000 (95 % UI
2.8–3.6), and for females was 3.23 per 1,000 (95 % UI
2.3–3.6) (Fig. 3b).
Prevalence of adult congenital heart disease
Figure 3a shows the prevalence of recalled CHD over time
by age group. In 1968, there were 118,000 (95 % UI
72,000–150,000) adults with recalled CHD. By 2010, there
was an increase by a factor of 2.3 (95 % UI 2.2–2.6) to
273,000 (95 % UI 190,000–330,000) adults. In 2010, there
were 134,000 (95 % UI 69,000–160,000) reproductive-age
females (age 15–49 years) with recalled CHD.
The estimated number of adults (age 20 to 64 years)
with recalled CHD, as well as the trends in prevalence
from 1970 to 2050, are shown in Table 1 and displayed
visually in Fig. 4. There will be an estimated 355,000
(95 % UI: 266,000–415,000) adults age 20 to65 years
with CHD in 2025 and 510,000 (95 % UI: 400,000–
580,000) in 2050. This corresponds to an estimated 1.47
per thousand adults with CHD in 2010, 1.83 per
thousand adults in 2025, and 2.31 per thousand adults
in 2050. The prevalence of adults with recalled CHD be-
gins to plateau around the year 2050 and growth in the
total number of adults with CHD slows to match the
general population growth.
In 2010, the number of adolescents with recalled CHD
who turned 20 years old was 9,800 (95 % UI: 7,700–
11,000). This number will increase by a factor of 1.29 to
13,000 (95 % UI: 10,000–14,000) in 2050. In addition,
there will be 170,000 (95 % UI: 100,000–200,000)
reproductive-age females in 2025 and 216,000 (95 % UI:
140,000–250,000) in 2050.
Main findings
We found 273,000 adults had recalled CHD in 2010,
which corresponds to 1.47 per thousand people. This
estimate is lower than a recent meta-analysis, which
found the adult CHD population prevalence to be
around three per thousand, but they were limited by the
large heterogeneity of the studies and did not include
the US [13]. Our integrative systems model confirms
that the population of adults with CHD is increasing;
however, we are the first to note that the prevalence will
start to plateau around the year 2050 unless there are
significant changes in birth prevalence or mortality. This
has implications for the health care system since it
allows us to quantify the magnitude of this patient popu-
lation and help with planning for their future healthcare
needs. Previous observational studies of adults with
CHD have focused on the severity distribution, and
found that severe cases constitute 3 % and moderate
cases 15 % of the total; none have projected future popu-
lation trends [4, 13, 28]. Registry data are thus far lack-
ing, and it is difficult to establish registries that capture
adult CHD patients with heterogeneous diseases who
may not receive regular healthcare [29]. Mathematical
Fig. 2 Congenital-heart-disease-specific mortality rates as a function of time from 1970 to 2010, stratified by age group. (Markers show National
Vital Statistics System data and lines show model estimates.)
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modeling has been recommended as an important tool
for understanding the burden of this disease [22].
This study used integrative systems modeling to show
that the mortality from CHD has declined in all age
groups between 1968 and 2010 with children zero to
51 weeks having experienced the greatest decline,
followed by those 1–4 years, which is consistent with
prior studies that have shown a mortality decreased be-
tween 31 and 39 % in this population [2, 3, 30]. Despite
improvements in mortality, these age groups continue to
experience the highest mortality from CHD. Recent im-
plementation of newborn pulse oximetry screening pro-
grams for critical CHD [31], as well as increased
perinatal screening using genetic testing and fetal echo-
cardiography, allows earlier detection of CHD. Earlier
diagnosis will continue to decrease the infant mortality
since late diagnosis is associated with worse infant sur-
vival [32, 33]. However, we still have much work to do
in individuals aged 20 to 64 years old, whose mortality
has remained stable with little improvement over the
past 30 years [7]. Our data suggest that the mortality in
CHD beyond the neonatal period is shifted well into
adulthood, though still premature compared to the gen-
eral population.
The care of adult CHD patients requires specialized
training, which is being developed after the 2012 ap-
proval of adult CHD as a cardiology subspecialty by the
American Board of Medical Specialties. The current
American Heart Association and American College of
Cardiology guidelines recommend that adults with mod-
erate and severe CHD be seen every 12 to 24 months by
a cardiologist with specific CHD expertise at a regional
CHD center; the absence of symptoms is not a reliable
indicator of cardiac function [17, 34–36]. The leading
cause of death in the adult CHD population is sudden
death (26 %), followed by progressive heart failure (21 %)
and perioperative death (18 %) [34]. Unfortunately, less
than half of adolescent patients have adult cardiology
follow-up in a timely manner after they turn 18 years
old [19, 37].
This rapidly increasing CHD population in adults, as
well as the increasing population of atherosclerotic heart
Fig. 3 a Recalled congenital heart disease prevalence per 1000 as a function of age, stratified by year of birth. b Recalled prevalence per 1000 at
birth (solid red), for 1–4 year olds (dashed green), and for 5–19 year olds (dotted purple) as a function of time, based on data from the National
Health Interview Survey (circle and square markers)
Table 1 Estimated cases and prevalence of ACHD over time
1970 1980 1990 2000 2010 2020 2030 2040 2050
ACHD Cases (Thousands) 122 154 183 219 273 328 385 454 510
ACHD Prevalence (per 1000) 1.15 1.19 1.25 1.32 1.47 1.7 1.96 2.18 2.31
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disease in adults [38], will lead to a substantial increase
in health care utilization [39–41] and increase demand
for CHD trained cardiologists. It also requires an esti-
mated one specialized cardiac center per two million
population, which are not yet in place [42]. In addition,
CHD patients benefit from multi-disciplinary care team
to address their complex needs given their increased risk
for developmental disabilities [16], comorbidities [43],
and special considerations for patients desiring preg-
nancy [44, 45]. Collaborative and multidisciplinary
strategies are urgently needed, such as systems and
processes to improve transitions of care from
pediatric providers to the adult health care system
[20, 37, 46], improved specialized cardiac centers with
cardiologists trained in adult CHD management [42],
and technological and medical improvements in care
for these patients [42, 47].
Limitations
Our data on CHD prevalence come entirely from the
NHIS, a population-based household survey subject to
all the challenges of survey research. Although NHIS
has a high response rate (close to 90 %), it is possible
that there is differential non-response bias, where house-
holds with children with moderate to severe CHD are
more likely than average to refuse to be interviewed. We
attempted to minimize the bias that this would intro-
duce by excluding the data from those with children in
the zero to 51 week age group, and sensitivity analysis
(Additional file 3) showed that including it reduced the
overall prevalence by at most 4 %. CHD is a group of
individually rare diseases and so it is likely unrecalled or
unreported when present (it is also sometimes undiag-
nosed or diagnosed later in life, making recall impos-
sible). It is also possible that CHD is reported in cases
where it is not present, due to confusion about the
question. However, we believe that recalled CHD is an
underestimate of the overall prevalence of CHD, which
reflects the lack of public understanding, even among
those with the condition. As the question only asked for
children under the age of 18, it cannot capture CHD
cases diagnosed in adulthood. The recency effect pre-
dicts that this subpopulation would better recall their
CHD status than those diagnosed in childhood, but we
suspect that they constitute a small proportion of all
ACHD cases. Despite the large sample size of the NHIS,
recalled CHD is rare enough that the data are quite
noisy (Fig. 3b). Our results show that since 1997, there
has been a birth prevalence of recalled CHD of around
three per 1,000, which we would like to use as an esti-
mate of moderate to severe cases of CHD. This is lower
than recently published birth prevalence of four to seven
per 1,000 [1, 3–5]. At birth, about half of all CHD are
characterized as moderate to severe; in adulthood mod-
erate CHD accounts for around 38 % and severe around
15 % [13, 17]. Therefore, as the aim of our study was to
capture those aware of their moderate to severe CHD who
would survive to adulthood, to determine the current and
future population of adults that will enter the health care
system, we feel this reflects the minimum number of adult
CHD patients we would expect to engage in the health
system unless increased public health awareness on the
individual and population level are improved.
Our data on CHD mortality come from an ICD-coded
nationwide database, which may have a low specificity
due to miscoding. It may also be nonspecific [48] leading
to under-reporting [49] or over-reporting [50]; however,
the sensitivity of the system has remained largely the
same so the time trends should still be valid. The mor-
tality rates may be underestimates as the patient or fam-
ily and provider need to be aware of the CHD diagnosis
in order for it to be coded on the death certificate. We
Fig. 4 Estimated number of adults (ages 20 to 64 years) with recalled congenital heart disease cases (blue solid line) and prevalence of recalled
congenital heart disease in adults (per 1000) (green dotted line), with 95 % uncertainty intervals shaded in grey, as a function of time, from 1965
to 2060. Previous estimates of ACHD prevalence are marked with circles for comparison
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noted minor variations in the data between ICD 8 and 9
and between 9 and 10 but this did not change the mor-
tality trends. An alternative line of research has used
National Birth Defects Prevention Network (NBDPN)
data to investigate the survival rates for (and birth preva-
lence of) specific defects [6, 9–12, 51]. This provides com-
plementary information to our study, but, since it has
been more focused in its cause lists (e.g. considering birth
prevalence or survival for hypoplastic left heart syndrome
only [52]), it cannot be incorporated directly into our
model. Developing estimates and projections for more fo-
cused cause lists that bring together NBDPN measure-
ments and death certificate data is an interesting direction
for future work. We anticipate that future researcher will
use other approaches and/or refine those used here to fur-
ther add to our knowledge of the prevalence of ACHD.
Our finding of decreased infant mortality is consistent
with other studies and is not likely due to a decrease in
births, which was adjusted for in our model. Other pos-
sible explanations are also unlikely, but include a de-
creasing birth prevalence with an increasing diagnosis of
CHD. However, published studies suggest the opposite,
with slightly increased birth prevalence given the in-
crease in the diagnosis with perinatal screening with
fetal echocardiography and neonatal screening with
pulse oximetry [1, 3, 5, 30, 53]. Also, birth prevalence
may increase with increased number of adults with CHD
having children with CHD [54]; however, this may be
offset by increased termination of pregnancy due to high
complex CHD malformations [55]. Data related to ter-
mination of pregnancy are limited and trends are
unknown [56]. Thus, our findings of an increased popu-
lation of adults with recalled CHD due to the decrease
in mortality and increased life expectancy will lead to a
growing population in the future.
Conclusion
In this study we estimated and projected future preva-
lence and population trends of adults with recalled CHD
using an integrative systems model. The use of death
certificates, which record nearly all deaths, and NHIS
population-based data, enabled us to assess the impact
of CHD on essentially the entire population, not only
those who undergo surgery or who are seen at special-
ized cardiac centers. We found a 3.2-fold decreased
mortality in 0 to 51-week-olds and a rapidly increasing
population of adults with CHDs that will start to plateau
by the year 2050. There is a need for increased aware-
ness and understanding of the term “CHD”, both indi-
vidually and on the population level, with improved
transitions from pediatric to adult care and an adult
health care system that is prepared for the complex
needs of this population.
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